Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
LetterLetter

Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database

CAMILLE METTLER, LAURENT CHOUCHANA and BENJAMIN TERRIER
The Journal of Rheumatology August 2020, 47 (8) 1298-1300; DOI: https://doi.org/10.3899/jrheum.200023
CAMILLE METTLER
Département de Médecine Interne, Centre de Référence National pour les maladies autoimmunes systémiques rares, Hôpital Cochin, AP-HP;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for CAMILLE METTLER
LAURENT CHOUCHANA
Département de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Cochin, AP-HP;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for LAURENT CHOUCHANA
BENJAMIN TERRIER
Département de Médecine Interne, Centre de Référence National pour les maladies autoimmunes systémiques rares, Hôpital Cochin, AP-HP, and Université Paris Descartes, Paris, France.
Roles: Professor
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for BENJAMIN TERRIER
  • For correspondence: benjamin.terrier@aphp.fr
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Aortitis is a rare inflammatory disease ranging from asymptomatic aortic thickening to life-threatening manifestations, especially aortic dissection or stenosis. Aortitis mainly occurs during systemic inflammatory diseases (giant cell arteritis, Takayasu arteritis, IgG4-related disease) and less frequently in patients with syphilis or tuberculosis1. Aortitis is rarely suspected to be induced by drugs and its causality is hardly assessable. The aim of our study is to identify drugs associated with aortitis occurrence using a data-mining approach.

We used VigiBase, the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database, which contains reports of suspected adverse drug reactions (ADR) collected by national drug authorities in more than 130 countries. The database is automatically deduplicated by VigiBase; further, a case-by-case review has been performed to exclude possible duplicates. This makes it powerful for the conduct of disproportionality analyses. This pharmacovigilance statistical method, based on a case/non-case approach, estimates whether an adverse event is differentially reported for a drug compared to other drugs. The association can be expressed using the reporting OR (ROR) and its CI for each drug adverse event combination. This approach has proven its interest for the detection of safety signals2. To identify drugs associated with aortitis occurrence, we extracted ICSR recorded in VigiBase from inception in 1967 until June 30, 2019, with the ADR “aortitis.” According to the European Medicines Agency, threshold for signal detection is defined as an ROR lower boundary 95% CI ≥ 1 and a number of cases ≥ 33. Drugs not reported in at least 3 ICSR and 2 different countries have been excluded. To limit reporting bias, comparators were all drugs of the Anatomical Therapeutic Chemical (ATC) class L (antineoplastic and immunomodulating agents).

VigiBase is a fully anonymized database of spontaneous reports from WHO; access is granted for national or regional pharmacovigilance centers, such as our team. The information within VigiBase, a global pharmacovigilance database, comes from a variety of sources, and the probability that the suspected adverse effect is drug-related is not the same in all cases. According to French law, ethics board approval is not mandatory for studies on an anonymous pharmacovigilance database. The present analysis does not represent the opinion of the University Medical Center (UMC) or the WHO, and reflects only the authors’ opinions.

Of the 19,834,180 ICSR in VigiBase, 162 aortitis cases have been identified, reported with 95 different suspected drugs. After exclusion of ICSR reported in only 1 country (n = 58) and suspected drugs reported in less than 3 different ICSR (n = 2), we retained 102 ICSR corresponding to 18 suspected drugs. Aortitis ICSR were reported by physicians in 62.7%, other health professionals in 22.5%, consumers in 6.9%, and pharmacists in 3.9%; reporter qualification was unknown in 3.9%. Mean age at the onset of aortitis was 58 ± 13 years; 70% of patients were female. Reports originate mainly from Japan (31%), United States (27%), Canada, and Sweden (7% each). Figure 1 indicates for each suspected drug the number of cases and corresponding ROR for aortitis. Of the 18 suspected drugs, 9 are associated with a significant ROR for aortitis, meaning a possible pharmacovigilance signal. Strikingly, all these drugs were antineoplastic and immunomodulating agents (ATC L class): granulocyte colony-stimulating factor (G-CSF) drugs (lipegfilgrastim, lenograstim, filgrastim, pegfilgrastim), epirubicin, nivolumab, tocilizumab (TCZ), trastuzumab, and rituximab (RTX).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Drugs associated with aortitis reporting within the WHO pharmacovigilance database, and ROR. Left panel shows the number of cases and ROR of aortitis ICSR and right panel shows the forest plot of ROR and their 95% CI. Of note, 1 ICSR can include more than 1 suspected drug. ROR (95% CI) are calculated as ad/bc (e ^(± 1.96 √(1/a+1/b+1/c+1/d))), where a is the number of aortitis cases reported for the suspected drug, b is the number of other ADR cases reported for the suspected drug, c is the number of aortitis cases reported with the comparator drugs, and d is the number of other ADR cases reported for the comparator drugs. If the CI does not include 1, the ROR is considered significant and is interpreted as indicating an association between the drug and the occurrence of aortitis. WHO: World Health Organization; ROR: reporting OR; ICSR: Individual Case Safety Report; ADR: adverse drug reaction.

Our analysis identified certain antineoplastic and immunomodulating agents as being strongly associated with the occurrence of aortitis, the strongest signal being for G-CSF drugs. This association has already been reported in case series and using pharmacovigilance databases4,5,6. However, some authors pointed out that aortitis was a rare adverse event of G-CSF and it was therefore difficult to assess the drug causality7. Our data strongly support the role of G-CSF drugs in the onset of aortitis. ICSR reported with epirubicin or trastuzumab also included G-CSF drugs as concomitant medications. The causal relationship of epirubicin or trastuzumab and aortitis is therefore questionable (Table 1). Aortitis ICSR reported with TCZ and RTX involved patients treated for aortitis or inflammatory diseases associated with aortitis, suggesting treatment failure. In contrast, patients treated with nivolumab were not receiving any concomitant medication, especially G-CSF, strengthening a causal relationship with aortitis. Of note, of the 6 aortitis ICSR associated with nivolumab and reported in VigiBase, 2 had also been reported in the literature8,9. For the 2 drugs likely to induce aortitis, G-CSF and nivolumab, time to onset was available in 12 and 3 patients, respectively8,9. In these patients, median time to aortitis onset was 8 days (range 3–34 days) and 285 days (range 275–305 days) after initial exposure to G-CSF and nivolumab, respectively. Intrinsic limitations of this analysis, as in other studies based on pharmacovigilance database, include underreporting and a heterogeneous causality assessment among ICSR due to different pharmacovigilance practices. However, aortitis is an expert physician diagnosis that is trustworthy, and that limits the reporting bias. Finally, although our study design cannot estimate the extent of drug-induced aortitis risk, it is powerful to find out unidentified ADR.

View this table:
  • View inline
  • View popup
Table 1.

Detailed description of aortitis cases reported with epirubicin, nivolumab, RTX, TCZ, or trastuzumab.

Our study shows a likely safety signal for aortitis with G-CSF and nivolumab. Physicians should consider aortitis in case of abdominal and/or chest pain and increased acute-phase reactants in patients receiving these drugs. These findings also support roles for G-CSF and programmed cell death protein 1 in the pathophysiology of large vessel inflammation. They need to be confirmed in further studies, especially experimental studies.

REFERENCES

  1. 1.↵
    1. Bossone E,
    2. Pluchinotta FR,
    3. Andreas M,
    4. Blanc P,
    5. Citro R,
    6. Limongelli G,
    7. et al.
    Aortitis. Vascul Pharmacol 2016;80:1–10.
    OpenUrl
  2. 2.↵
    1. Rothman KJ,
    2. Lanes S,
    3. Sacks ST
    . The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 2004;13:519–23.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Candore G,
    2. Juhlin K,
    3. Manlik K,
    4. Thakrar B,
    5. Quarcoo N,
    6. Seabroke S,
    7. et al.
    Comparison of statistical signal detection methods within and across spontaneous reporting databases. Drug Saf 2015;38:577–87.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Parodis I,
    2. Dani L,
    3. Notarnicola A,
    4. Martenhed G,
    5. Fernström P,
    6. Matikas A,
    7. et al.
    G-CSF-induced aortitis: two cases and review of the literature. Autoimmun Rev 2019;18:615–20.
    OpenUrl
  5. 5.↵
    1. Lardieri A,
    2. McCulley L,
    3. Jones SC,
    4. Woronow D
    . Granulocyte colony-stimulating factors and aortitis: a rare adverse event. Am J Hematol 2018;93:E333–6.
    OpenUrl
  6. 6.↵
    1. Oshima Y,
    2. Takahashi S,
    3. Tani K,
    4. Tojo A
    . Granulocyte colony-stimulating factor-associated aortitis in the Japanese Adverse Drug Event Report database. Cytokine 2019;119:47–51.
    OpenUrl
  7. 7.↵
    1. Bidhendi Yarandi R,
    2. Panahi MH
    . Is granulocyte colony-stimulating factor associated with development of aortitis? Cytokine 2019;120:191.
    OpenUrl
  8. 8.↵
    1. Roy AK,
    2. Tathireddy HR,
    3. Roy M
    . Aftermath of induced inflammation: acute periaortitis due to nivolumab therapy. Case Rep 2017;2017:bcr-2017-221852.
    OpenUrl
  9. 9.↵
    1. Loricera J,
    2. Hernández JL,
    3. García-Castaño A,
    4. Martínez-Rodríguez I,
    5. González-Gay MÁ,
    6. Blanco R
    . Subclinical aortitis after starting nivolumab in a patient with metastatic melanoma. A case of drug-associated aortitis? Clin Exp Rheumatol 2018;36 Suppl 111:171.
    OpenUrl
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 47, Issue 8
1 Aug 2020
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database
CAMILLE METTLER, LAURENT CHOUCHANA, BENJAMIN TERRIER
The Journal of Rheumatology Aug 2020, 47 (8) 1298-1300; DOI: 10.3899/jrheum.200023

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Antineoplastic Drug-induced Aortitis: An Unraveled Adverse Effect Using the World Health Organization Pharmacovigilance Database
CAMILLE METTLER, LAURENT CHOUCHANA, BENJAMIN TERRIER
The Journal of Rheumatology Aug 2020, 47 (8) 1298-1300; DOI: 10.3899/jrheum.200023
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Rapidly Progressive Systemic Sclerosis–associated Interstitial Lung Disease After Intravesical Bacillus Calmette-Guérin Therapy for Early-stage Bladder Cancer
  • Axial Involvement in Psoriatic Arthritis: Effect on Peripheral Arthritis and Differential Features With Axial Spondyloarthritis in South America
  • The Effect of HLA-B27 on Susceptibility and Severity of COVID-19
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire